Share Name Share Symbol Market Type Share ISIN Share Description
Provexis Plc LSE:PXS London Ordinary Share GB00B0923P27 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 0.45 1,339,757 00:00:00
Bid Price Offer Price High Price Low Price Open Price
0.40 0.50 0.00 0.00 0.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Food Producers 0.32 -0.53 -0.03 9
Last Trade Time Trade Type Trade Size Trade Price Currency
15:32:05 O 40,000 0.4536 GBX

Provexis (PXS) Latest News

More Provexis News
Provexis Takeover Rumours

Provexis (PXS) Discussions and Chat

Provexis (PXS) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Provexis trades in real-time

Provexis (PXS) Top Chat Posts

Provexis Daily Update: Provexis Plc is listed in the Food Producers sector of the London Stock Exchange with ticker PXS. The last closing price for Provexis was 0.45p.
Provexis Plc has a 4 week average price of 0.40p and a 12 week average price of 0.30p.
The 1 year high share price is 0.45p while the 1 year low share price is currently 0.21p.
There are currently 1,983,988,174 shares in issue and the average daily traded volume is 2,765,433 shares. The market capitalisation of Provexis Plc is £8,927,946.78.
twodegrees: why the sudden spike in the share price. seems to be some steady buying going on and yet no news.
wheelds: News article:- )Note By-Health sole expense) and share price ended up 12%. "Provexis, up 17%. The food ingredients retailer signed a collaboration agreement with Chinese dietary supplement firm By-Health Co Ltd for the launch of Fruitflow-based products in China. The agreement has been structured on an open-ended framework basis, which will allow both companies to conduct several different projects over an unspecified period of time, to be at By-Health sole expense. Projects conducted under the agreement will be focused on specific areas of commercial focus for By-Health, with the first project to concentrate on the use of Fruitflow with nitrates in exercise. The nitrates project is expected to provide gross income to Provexis in excess of GBP55,000, and will now affect the company's ownership of existing intellectual property for the nitrates formulation. Project work is to be managed and conducted by Provexis mainly in the UK, and supported by outsourced research partners that will be appointed by the company."
wheelds: With regard to the long term alliance between DSM and Provexis and now By-Health the Chinese company who is spending its own money on further research of the health benefits of Fruitflow all highlights to me that something very big is in the pipe line:- (note Dr.Niamh, our research chemist, appointed to board with immediate effect has been working for Provexis since the year 2000. So why now???. And we now have an executive director of DSM on our board. Note:-"pioneering new and significant applications." (and we now have our own Dr.Niamh on board to verify new products which must be from the Chinese research.IMHO From Provexis news:- "The Alliance with DSM will give DSM exclusive global rights to Fruitflow and will see the partners collaborate to develop Fruitflow® in all major global markets, through an effective commercialisation of current formats and pioneering new and significant applications." "Strategy, co-ordination, organisation and implementation will be governed by an Alliance Board with representatives from both companies. The agreement is based on a long-term cooperation between the partners." And the last RNS on the 12th April 2019:- (stating with immediate effect) and thats on top of DSM's executive Director with all his global contacts just recently appointed to Provexis board, clearly shows to me that some thing very big is in the Pipe Line as Dr Niamh O'Kennedy who has been working with Provexis since the year 2000 has now been appointed as an executive director representing Provexis in the partnership.. (some thing big in the pipe line in my opinion,) something to do with the collaboration deal between Provexis and DSM and the Chinese company By-Health who is further researching the many benefits of Fruitflow at its own cost. . IMHO All looking good and the last time a collaboration deal was going on between Provexis and Co ca Cola the share price shot up from 0.6p to 15p in less then a year until the deal fell through.. "Niamh is a research chemist, specialising in the field of natural products chemistry, who has been working with Provexis since 2000. Niamh's experience in isolating and characterising plant-derived compounds and understanding the roles these play in complex biological systems has been pivotal in the development of Provexis' lead product, Fruitflow®;, and the health claim for Fruitflow®; which was adopted by the European Food Safety Authority ('EFSA')."
wheelds: In my opinion, in 3 years time the share price should break the PXS record high of 15p if the China deal works out and if DSM continue to increase its profits by selling more and more of Fruitflow products around the world. Provexis has already spent lots of money on Patents around the world, hence increase spending should now be less and revenue higher and higher and the share price will reflect these factors.IMHO
wheelds: Last time when the potential deal with Coca cola the share price based on just potential rose from 0.6p to 15p over just one year. And then Coca cola pulled out on the deal and the share price since then has just dropped and dropped. Today we have a potential deal with the Chinese company By-Health and as it gets closer to an agreed deal the share price will rise and rise again. IMHO
bareknee: Graham Just to echo what RedPrince has already said ... hopefully what went wrong in 2018 for you can be fixed, and 2019 is a better year. What happens on the markets might effect our wealth, but that's not the most important thing in life. So Happy New Year to anyone reading this, and I hope 2019 brings health and happiness to you ... though any rise in the share price would be welcomed as well ! BB
wheelds: What has sparked it off? In my opinion, The news today that America and North Korea have come to an agreement. Hence, By-health the Chinese company, neighbour to North Korea, can now plan to produce, at a lower cost, Fruitflow porducts and sell acrosse Asia and in time even to America and Europe. Hence, in my opinion, we should soon get official news as to the progress of the colaboration deal with Provexis and DSM and the 1.3 billioon dollar Chinese company BY-hEALTH aS TO THEIR GLOBAL PLANS FOR OUR FRUITFLOW; and based on potential we will see the Share price rise and rise over the next couple of years.IMHO
gunsofmarscapone: How sad is it, when the investors have to buy the condensed tomato extract (inc me) in a vain attempt to show solidarity. If you guys were honest you would do as I did and admit that, unless for some strange reason entering at 0.4p, it was a MASSIVE AND STUPID ERROR to assume that the medical efficacy of this substance (yes it is brilliant) correlated in any mathematical respect to the share price. Pxs owes me 1K now and will retain a few hundred k shares LTH.
wheelds: Its worth pointing out that the share price keeps rising and on some sites the bid price is stated as 0.7p. I am looking forward to see what the share price and bid price starts up on Monday. But because we only have good news to come, in my opinion, the share price should now keep rising relative to potential and actual increased revenues.IMHO
wheelds: Looks like the next RNS will bring a share price rise:- (8 out of 10 Up) 07:00 20-Dec-2016 PXS Fruitflow and Blood Pressure - second stage update RNS +18.62% Up 07:00 23-Nov-2016 PXSStudy publication - comparison with aspirin RNS +87.90% Up 09:46 18-Nov-2016 PXS New Collaboration for Fruitflow RNS +50.00% Up 15:33 30-Sep-2016 PXS Result of AGM RNS +5.85% Up 17:08 15-Sep-2016 PXS Director/PDMR Shareholding RNS -1.46% Down 07:00 07-Sep-2016 PXS Preliminary Results RNS -6.49% Down 10:23 02-Sep-2016 PXS Holding(s) in Company RNS +9.27% Up 07:00 02-Aug-2016 PXS Results of Placing RNS +2.44% Up 07:00 12-Jul-2016 PXS Study Publication RNS +5.39% Up 07:05 29-Jun-2016 PXS Funding Update RNS +8.61% Up 07:00 29-Jun-2016 PXS Product Launch RNS +8.61% Up -------------------------------------------------------------------------------------------------------------------------------------------------------
Provexis share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191209 19:21:56